Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 8;25(6):3141.
doi: 10.3390/ijms25063141.

Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies

Zihao Wu  1 , Jillian Lu  1 , Andrew Loo  1 , Nathan Ho  1 , Danny Nguyen  1 , Po Yueh Cheng  1 , Ali I Mohammed  1 , Nicola Cirillo  1   2
Affiliations

Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies

Zihao Wu et al. Int J Mol Sci. .

Abstract

Cluster of differentiation 44 (CD44), a cell surface adhesion molecule overexpressed in cancer stem cells, has been implicated in chemoresistance. This scoping review, following PRISMA-ScR guidelines, systematically identified and evaluated clinical studies on the impact of CD44 expression on chemotherapy treatment outcomes across various cancer types. The search encompassed PubMed (1985-2023) and SCOPUS (1936-2023) databases, yielding a total of 12,659 articles, of which 40 met the inclusion criteria and were included in the qualitative synthesis using a predefined data extraction table. Data collected included the cancer type, sample size, interventions, control, treatment outcome, study type, expression of CD44 variants and isoforms, and effect of CD44 on chemotherapy outcome. Most of the studies demonstrated an association between increased CD44 expression and negative chemotherapeutic outcomes such as shorter overall survival, increased tumor recurrence, and resistance to chemotherapy, indicating a potential role of CD44 upregulation in chemoresistance in cancer patients. However, a subset of studies also reported non-significant relationships or conflicting results. In summary, this scoping review highlighted the breadth of the available literature investigating the clinical association between CD44 and chemotherapeutic outcomes. Further research is required to elucidate this relationship to aid clinicians in managing CD44-positive cancer patients.

Keywords: CD44; chemoresistance; chemotherapy; clinical outcome; hyaluronic acid; treatment outcome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA-ScR diagram of the article selection process (last search in June 2023).
See this image and copyright information in PMC

References

    1. Liu F.S. Mechanisms of chemotherapeutic drug resistance in cancer therapy—A quick review. Taiwan J. Obstet. Gynecol. 2009;48:239–244. doi: 10.1016/S1028-4559(09)60296-5. - DOI - PubMed
    1. Rieth J., Subramanian S. Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. Int. J. Mol. Sci. 2018;19:1340. doi: 10.3390/ijms19051340. - DOI - PMC - PubMed
    1. Gee K., Kryworuchko M., Kumar A. Recent advances in the regulation of CD44 expression and its role in inflammation and autoimmune diseases. Arch. Immunol. Ther. Exp. 2004;52:13–26. - PubMed
    1. Mackay C.R., Terpe H.J., Stauder R., Marston W.L., Stark H., Gunthert U. Expression and modulation of CD44 variant isoforms in humans. J. Cell Biol. 1994;124:71–82. doi: 10.1083/jcb.124.1.71. - DOI - PMC - PubMed
    1. Aruffo A., Stamenkovic I., Melnick M., Underhill C.B., Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell. 1990;61:1303–1313. doi: 10.1016/0092-8674(90)90694-A. - DOI - PubMed

Publication types

LinkOut - more resources